Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN9220 + Odronextamab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphomas
NCT07887750Phase 2Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2026
- Primary completion
- Nov 2029
01
Overview
A Phase 2 trial of REGN9220 in diffuse large B-cell lymphoma (DLBCL), sponsored by Regeneron Pharmaceuticals. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
REGN9220
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07887750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07887750.